SERVICES OVERVIEW
Poor translatability of traditional in vitro models has a major impact on drug attrition leading to only 8% of new drugs that show preclinical efficacy progressing after Phase I trials. It’s time to rethink convention.
HUB Organoids closely recapitulate patient pathobiology, providing superior preclinical models for your compound testing and closing the gap to clinical trials. HUB Organoids can support decision-making at every step of your drug development pipeline and help you bring life-changing treatments to patients.
Leverage the predictive power of HUB Organoids to select the most promising clinical candidates with confidence
Innovate novel disease models and assays and bring your research to the next level
Accurately stratify and customize patient treatment with our co-clinical testing platform
CONTENT HIGHLIGHT
Read our proof-of-concept study that demonstrates how HUB Organoids can streamline the entire preclinical drug development process, resulting in significant savings in time, cost, and resources.
ON-DEMAND WEBINAR
